Home » Stocks » PACB

Pacific Biosciences of California, Inc. (PACB)

Stock Price: $35.22 USD 4.65 (15.21%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $36.48 +1.26 (3.58%) Mar 1, 7:59 PM
Market Cap 6.84B
Revenue (ttm) 78.89M
Net Income (ttm) 29.40M
Shares Out 165.19M
EPS (ttm) 0.17
PE Ratio 207.18
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $35.22
Previous Close $30.57
Change ($) 4.65
Change (%) 15.21%
Day's Open 32.69
Day's Range 31.84 - 35.69
Day's Volume 6,072,463
52-Week Range 2.20 - 53.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conf...

Investors Business Daily - 3 days ago

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: PFE, MRNA
Investors Business Daily - 3 days ago

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: AZN, BNTX, GILD, GSK, ILMN, JNJ, LLY, MRNA, NVAX, PFE, REGN, TMO, VIR
Zacks Investment Research - 6 days ago

Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.

Other stocks mentioned: LH
Forbes - 1 week ago

The stock price of Pacific Biosciences of California a biotechnology company that develops gene sequencing systems, has seen a solid 27% rise over the last ten trading days, though it's down 4...

GlobeNewsWire - 1 week ago

Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S. Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S.

GuruFocus - 2 weeks ago

Will SoftBank Group Corp.'s (SFTBY) huge investment in Pacific Biosciences of California Inc.(NASDAQ:PACB) turn out to be another home run for the Japanese conglomerate or will it be a swing a...

Zacks Investment Research - 2 weeks ago

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

Benzinga - 2 weeks ago

ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 fo...

Other stocks mentioned: ANAB, EPIX
24/7 Wall Street - 2 weeks ago

With the trading day more than halfway over, the broad markets were trading sideways on Thursday.

Other stocks mentioned: CSCO, LYFT, UBER, VMW, CCJ, IRBT, MELI, PCRX, SUMO
The Motley Fool - 2 weeks ago

The pandemic didn't weigh on the genetic sequencing systems company nearly as much as earlier in 2020.

The Motley Fool - 2 weeks ago

The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.

The Motley Fool - 2 weeks ago

The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.

Zacks Investment Research - 2 weeks ago

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for ...

Benzinga - 2 weeks ago

Shares of Pacific Biosciences (NASDAQ:PACB) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 0.00% over the past year to $0.37, ...

GlobeNewsWire - 2 weeks ago

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31...

The Motley Fool - 2 weeks ago

Pacific Biosciences is getting an investment from a holding company.

GlobeNewsWire - 2 weeks ago

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms...

Benzinga - 2 weeks ago

SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of ...

Other stocks mentioned: SFTBY
Zacks Investment Research - 2 weeks ago

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

Benzinga - 2 weeks ago

On Wednesday, February 10, Pacific Biosciences (NASDAQ:PACB) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

GlobeNewsWire - 3 weeks ago

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequen...

The Motley Fool - 3 weeks ago

A new leadership team is betting that it can make long-read genome sequencing more competitive.

GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequen...

GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financia...

Forbes - 1 month ago

After a large 13x rise since the March 23 levels of last year, at the current price of around $36 per share we believe Pacific Biosciences of California stock, a biotechnology company that dev...

Zacks Investment Research - 1 month ago

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.

Zacks Investment Research - 1 month ago

Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.

GlobeNewsWire - 1 month ago

New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care New platform expected to make whole genome sequencing sign...

GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long ...

GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today ann...

GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appoi...

GlobeNewsWire - 1 month ago

Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel I...

Zacks Investment Research - 1 month ago

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

Other stocks mentioned: ABMD, MDRX
Zacks Investment Research - 2 months ago

Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.

GlobeNewsWire - 2 months ago

MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequen...

Benzinga - 2 months ago

BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Fa...

Other stocks mentioned: HCA, BCDA
Zacks Investment Research - 2 months ago

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects.

Zacks Investment Research - 2 months ago

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 3 months ago

MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its pre...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its co...

Zacks Investment Research - 3 months ago

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter.

The Motley Fool - 3 months ago

The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales.

Seeking Alpha - 3 months ago

Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -6.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020.

Zacks Investment Research - 4 months ago

Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements.

Other stocks mentioned: HSIC, INSP, STE
Zacks Investment Research - 4 months ago

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial...

Zacks Investment Research - 4 months ago

Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology.

About PACB

Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Oct 27, 2010
CEO
Christian O. Henry M.B.A.
Stock Exchange
NASDAQ
Ticker Symbol
PACB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is 51.50, which is an increase of 46.22% from the latest price.

Price Target
$51.50
(46.22% upside)
Analyst Consensus: Buy